Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver

Figure 1 Images obtained in the case of a 38-year-old man with systemic chemotherapy-resistant multiple hepatic metastases from a pancreatic neuroendocrine tumor. A: Arterial phase image of contrast-enhanced computed tomography (CT) shows well-enhanced metastatic tumors (arrows) as well as a hypodense tumor due to cystic degeneration with marginal enhancement (arrowhead); B: A selective hepatic angiogram delineates innumerable hypervascular metastatic tumors throughout the liver; C: Arterial phase image of contrast-enhanced CT at 3 mo after chemoembolization with miriplatin-iodized oil suspension demonstrates a significant reduction in the size of all lesions, with compact accumulation of iodized oil in the hypervascular tumors (arrows). It should be noted that the tumor with cystic degeneration was also reduced in size (arrowhead).

Figure 2 Images obtained in the case of a 35-year-old woman with a solitary neuroendocrine metastasis of the liver. A: Arterial phase image of contrast-enhanced computed tomography (CT) before intervention shows a hyperdense metastatic tumor in the right posterior segment surrounded by arterioportal shunting (arrow); B: Selective angiogram from the right posterior arterial segment delineates a single hypervascular metastatic tumor with arterioportal shunting; C: Arterial phase image of contrast-enhanced CT at 3 mo after chemoembolization with miriplatin-iodized oil suspension demonstrates a significant reduction in tumor size with compact accumulation of iodized oil accompanied by surrounding arterioportal shunting (arrow).